Galderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss

Contributed by: Business Wire

Logo

Tags

Research

Clinical Trials

Biotechnology

Other Health

Health

Pharmaceutical

General Health

Other Science

Science

Injectable Aesthetics portfolio

More Like This

Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss

ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline

Galderma Demonstrates Injectable Aesthetics Leadership in Medication-Driven Weight Loss With New Research and First International Consensus-Based Guidelines

AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community

AMWC Dubai: Galderma Demonstrates Injectable Aesthetics Leadership Through Updates on Its Scientific Innovations and Community Education

Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile

AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio

IMCAS 2025: Galderma’s Broad Presence and New Data on Recently Launched Products Restylane® SHAYPE™ and Relfydess® Reaffirm Its Category Leadership